The outlook and analysis of Soleno Therapeutics Inc (SLNO)’s stock

A share price of Soleno Therapeutics Inc [SLNO] is currently trading at $51.33, up 2.15%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SLNO shares have gain 0.69% over the last week, with a monthly amount glided 20.66%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on December 02, 2024, when Stifel reiterated its Buy rating but kept the price target unchanged to $74 for it. Previously, Robert W. Baird reaffirmed its Outperform rating on December 02, 2024, and kept the price target unchanged to $72. On September 03, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $70 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $72 on May 10, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $93 as its price target on February 05, 2024. Stifel started tracking with a Buy rating for this stock on January 23, 2024, and assigned it a price target of $63.

Soleno Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $36.61 and $60.92. Currently, Wall Street analysts expect the stock to reach $69.67 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $51.33 at the most recent close of the market. An investor can expect a potential return of 35.73% based on the average SLNO price forecast.

Analyzing the SLNO fundamentals

Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -39.95%, Pretax Profit Margin comes in at -38.06%, and Net Profit Margin reading is -38.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.62 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.54 points at the first support level, and at 49.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.77, and for the 2nd resistance point, it is at 52.21.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Soleno Therapeutics Inc [NASDAQ:SLNO] is 17.26. In addition, the Quick Ratio stands at 17.26 and the Cash Ratio stands at 3.24.

Transactions by insiders

Recent insider trading involved Yen Kristen, that happened on Jan 02 ’25 when 2520.0 shares were sold., Yen Kristen completed a deal on Jan 03 ’25 to sell 2340.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Mackaness James H sold 4083.0 shares on Jan 02 ’25.

Related Posts